Navigation Links
Researchers find a treatment for deadly brain tumor
Date:1/19/2010

Providence, RI New research at Rhode Island Hospital has identified a treatment in animal models for glioblastomas deadly brain tumors which, once diagnosed, offer a poor prognosis and relatively short life expectancy. Using a synthetic form of a naturally-occurring hormone combined with chemotherapy, researchers were able to inhibit tumor growth and achieve a 25 percent cure rate. The study and their findings are published in the Journal of Oncology.

Led by Suzanne de la Monte, MD, MPH, of Rhode Island Hospital, researchers studied the effects of Thymosin Alpha 1 (Talpha1/thymalfasin), a synthetic form of the naturally occurring hormone Thymosin produced by the thymus gland. De la Monte, who is also a professor of neuroscience at The Warren Alpert Medical School of Brown University, says, "Our hypothesis was that the immune system basically needs a boost to kill the cancer cells. We know that Thymosin is currently being used in Europe to treat cancer, so we set out to see what effect this could have on glioblastomas."

What the investigators found is that when Talpha1 was used alone, the tumor continued to eventually grow. When they combined the Talpha1 with a common chemotherapeutic agent, there was a dramatic effect. De la Monte explains, "We looked at giving chemo plus Talpha1 as a sort of immune booster. What we found is that when you give Talpha1 and the chemo agent together, not only do you have a slower rate of tumor growth with cells being killed, but there have also been cures. We achieved a 25 percent cure rate in these animal models."

Co-investigator Jack Wands, MD, also a physician with University Medicine Foundation and a professor Alpert Medical School, says, "In this study we used a natural hormone that's been produced in the thymus gland, which by itself has no anti-tumor effect and in fact can be harmful in high doses. What's important in this study is that we have found with low to moderate doses in combination with a well-known chemotherapeutic agent, it has a striking ability to inhibit the growth of a glioblastoma in animal models."

The researchers went on to further investigate how the Talpha1 was achieving this response. What they discovered is that it sensitizes the tumor cells to the chemotherapeutic agent, giving the agent more of an impact upon the tumor than it would have on its own. De la Monte explains, "The thymic hormone is actually working to boost immune response and basically activates a killing of the tumor cells."

De la Monte says the next step is to bring this to a Phase I clinical trial. "You're talking about a disease where people are dead within months. There is no cure." Wands agrees and says, "Our pre-clinical studies have shown this striking effect and we believe the next step is to try this approach in patients with this devastating illness."


'/>"/>

Contact: Nancy Cawley Jean
njean@lifespan.org
Lifespan
Source:Eurekalert

Related medicine news :

1. Researchers find new insights into inherited retinal disease
2. Pitt researchers raise concern over frequency of surveillance colonoscopy
3. Stress triggers tumor formation, Yale researchers find
4. Johns Hopkins researchers say vaccine appears to mop up leukemia cells Gleevec leaves behind
5. St. Johns wort not helpful treatment for irritable bowel syndrome, Mayo Clinic researchers say
6. Young hunters most likely to be injured using tree stands, say UAB researchers
7. Researchers find clues to why some continue to eat when full
8. Researchers find new patterns in H1N1 deaths
9. Researchers discover gene therapy to prevent progression of emphysema
10. Researchers at the John Theurer Cancer Center Present Cutting-Edge Research Results at this Years American Society of Hematology Annual Meeting
11. Vision researchers Jay and Maureen Neitz to receive first Pepose Award from Brandeis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... April 30, 2016 , ... Mercy College is expanding ... The following programs will be expanding due to high demand: Master of Business Administration ... will begin this summer. , School of Business Graduate Program Chair Dr. ...
(Date:4/29/2016)... ... April 29, 2016 , ... Shamangelic Healing, Sedona Arizona's ... brand Alpha BRAIN and New Mood Daily-Stress Formula for brain optimization and wellness ... to the store is just one more way Shamangelic Healing supports people’s quest ...
(Date:4/29/2016)... ... April 29, 2016 , ... Dr. ... of best seller "LOVE, MEDICINE and MIRACLES") addresses touchy topics related to Death ... podcasted thereafter . Dr. Bernie Siegel, author of a plethora of essential ...
(Date:4/29/2016)... ... April 29, 2016 , ... A new study ... severe congenital diaphragmatic hernia have better survival rates if surgery is performed early. ... condition where the diaphragm fails to form completely, letting abdominal organs into the ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... patented products, announces the Gyrociser, an exercise invention which aids in proper muscle ... says Scott Cooper, CEO and Creative Director of World Patent Marketing. "Globalization has ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... 28, 2016 Oramed Pharmaceuticals Inc. (NASDAQ: ... company focused on the development of oral drug delivery systems, ... PIONEERS 2016 conference, presented by Joseph Gunnar & ... New York . Nadav Kidron , CEO ... Presentation Details:   PIONEERS 2016, ...
(Date:4/28/2016)... New market research titled ... report that provides an overview of the Osteoarthritis,s ... identifying new targets and MOAs to produce first-in-class ... in this H1 2016 Osteoarthritis Pipeline report include ... Abiogen Pharma S.p.A., Ablynx NV, Achelios Therapeutics, Inc., ...
(Date:4/27/2016)... PARIS , April 27, 2016 ... Year-Over-Year Including 42% Growth in Recurring Consumable Sales  ... Mauna Kea Technologies (Euronext: MKEA, OTCQX: MKEAY) ... today announced its sales for the first quarter ended ... business and the execution of its commercial strategy. ...
Breaking Medicine Technology: